VYGR
Voyager Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.19
P/S
5.86
EV/EBITDA
-1.66
DCF Value
$-4.62
FCF Yield
-57.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-326.6%
Net Margin
-296.5%
ROE
-51.4%
ROA
-47.5%
ROIC
-56.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $15.3M | $-27.4M | $-0.47 |
| FY 2025 | $40.4M | $-119.7M | $-2.04 |
| Q3 2025 | $13.4M | $-27.9M | $-0.47 |
| Q2 2025 | $5.2M | $-33.4M | $-0.57 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.38
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.